Emilio Porfiri

Medicine · Health Sciences

29h-index5.5kcitations128works3.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(42), Cancer Genomics and Diagnostics(20), Prostate Cancer Treatment and Research(17), Renal and related cancers(17), Testicular diseases and treatments(11)

Publications127 total

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
The Lancet Oncology·2023· 85 citedOpen Access
Supplementary Table 11 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Table 7 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Table 11 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Data from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Table 5 and 6 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Table 9 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Table and Figure 1 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Data from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Table 8 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Tables 2, 3 and 4 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Table 10 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Tables 2, 3 and 4 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Table 7 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Table 9 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Table 10 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Table 8 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Table and Figure 1 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Supplementary Table 5 and 6 from MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome
2023Open Access
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
The Lancet Oncology·2023· 77 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Nicholas D. James(11), R. Cellerino(9), Sarah Pirrie(7), Duncan B. McLaren(5), Joe M. O’Sullivan(5), James Wylie(5), Alison Birtle(5), Prabir Chakraborti(5), Anjali Zarkar(5), Mehran Afshar(5), Bonnee Rubinfeld(4), Iris Albert(4), Paul Polakis(4), John F. Hancock(4), Ann Pope(4), Darren Barton(4), Stuart I. Collins(4), John Staffurth(4), Andrew Stanley(4), S. Beesley(4)